Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: population-based study by West, Joe et al.
© 2014 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY
nature publishing group  ORIGINAL CONTRIBUTIONS 757
 C
O
LO
N
/S
M
A
LL
 B
O
W
E
L 
see related editorial on page x
 INTRODUCTION 
 Population-based estimates of the incidence and prevalence of 
a disease are crucial for investigating the possible reasons for its 
occurrence and any changes in its underlying risk factors, but per-
haps more importantly to quantify the likely burden upon health-
care systems and society in general ( 1 ). For celiac disease (CD), 
numerous studies have been able to quantify the seroprevalence 
of positive anti-endomysial antibodies and / or anti-tissue trans-
glutaminase antibodies in single populations and at single points 
in time ( 2 ). With some variation, the overall seroprevalence has 
been surprisingly constant at around 1 % in most populations 
studied ( 3 ). Th is has not been the same for clinically recognized 
and diagnosed disease where disparities exist across time, place, 
and individual characteristics, which indicates that there are 
opportunities for improving diagnostic pathways and health out-
comes ( 4 – 9 ). 
 Although many epidemiological studies on the incidence and 
prevalence of clinically diagnosed CD have been carried out, rela-
tively few have spanned long periods of time, in the same popu-
lation, and studied both CD and dermatitis herpetiformis (DH) 
together ( 9 ). Th ose that have been published ( 10 – 15 ) are very 
small, have not included all age groups ( 16 ), are neither popu-
lation based nor nationwide (having focussed on, for example, 
only US military personnel ( 17 ) or specifi c regions of a country 
( 4,18 )), and have used variable disease defi nitions ( 19 ). Some 
incidence studies among children have shown a two- to threefold 
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increase in incidence of CD in Denmark and Sweden over a 
13-year period  (5,8), and another study in Scotland has shown 
a sixfold increase over 20 years ( 20 ), but no general population-
based longitudinal data (over multiple decades) are available for 
all regions of a nation for adult CD. Similar information for DH 
is not so readily available, but the information that is available 
mainly comes from Finland and suggests that DH is becoming 
less common  (21,22). Th is reduction is in direct contrast to CD 
( 4,14 ) and would be a surprising result if confi rmed, as both CD 
and DH are thought to share underlying pathophysiology. How-
ever, one intriguing possible explanation of such divergent trends 
might be that less exposure to gluten following a diagnosis of 
CD prevents DH from developing, as originally proposed by 
Salmi  et al ( 22 ). 
 To quantify the incidence and prevalence of clinically diagnosed 
CD and DH and to make comparisons with the known seropreva-
lence, we carried out a large population-based study across all 
regions of the United Kingdom using routinely available electronic 
medical data. We have therefore been able to determine variations 
in incidence and prevalence by age, sex, geographical region, and 
calendar time over a 22-year period. 
 METHODS 
 Study population 
 Data were extracted from the Clinical Practice Research Datalink 
(CPRD; version July 2012) accessed under the University of Not-
tingham ’ s CPRD license. Th ese data contain electronic informa-
tion on consultations, diagnoses, and prescriptions delivered in 
primary care in the United Kingdom, and have been validated for 
a wide variety of diagnoses ( 23 ). Th e accuracy of the diagnosis of 
CD in CPRD has also been specifi cally validated against medical 
records that were obtained previously for a sample of individuals 
and shown to be good ( 24 ). For this study, we used patients who 
were registered at a practice at some point from 1 January 1990 to 
31 December 2011 inclusive. Th is data set contains  ~ 57 million 
person-years of available data for analysis among 12 million con-
tributing patients within 644 general practices, and it is generally 
representative of the population of the United Kingdom. Within 
the data set, patients are labeled as  ‘ acceptable ’ for use in research, 
and data recorded do not raise concerns about validity and are 
recorded to the high research standard defi ned by CPRD. For this 
study, we only used  ‘ acceptable ’ patients. Th is study was approved 
by the Independent Scientifi c Advisory Committee of the CPRD 
(protocol 12_106R). 
 We identifi ed people with Read codes ( 25 ) representing CD 
(J690.00 celiac disease; J690.13 gluten enteropathy; J690z00 
celiac disease NOS; J690100 acquired celiac disease; J690.14 
sprue-nontropical; J690000 congenital celiac disease) or DH 
(M140.00 DH; M145200 senile DH; M142.00 juvenile DH). 
Patients could have a diagnosis of both CD and DH. Th e inci-
dence and prevalence for each diagnosis was calculated sepa-
rately, as described below. Th e date of the earliest recorded code 
for CD or DH was considered as the date of diagnosis for each 
case patient. 
 Cases were classifi ed as incident if their fi rst code representing CD 
or DH occurred at least 12 months aft er the patient ’ s date of reg-
istration with the general practitioner (GP) and aft er the fi rst date 
of up-to-standard data for the general practice. All other cases were 
considered prevalent. Th e methodology underpinning these defi ni-
tions are described in full elsewhere ( 24 ), have been used in other 
studies of CD using these data ( 26 ) and of incidence of other chronic 
gastrointestinal diseases i.e., infl ammatory bowel disease  (27,28). 
 Statistical analysis 
 We calculated crude incidence of CD and DH by dividing the 
number of newly diagnosed cases of each disease by the total 
follow-up time in the study period (1990 – 2011). We stratifi ed 
disease incidence by sex, age group (categorized  a priori as 0 – 4 
years, 5 – 17, 18 – 29, 30 – 49, 50 – 69 years, and 70 years and over), 
calendar year, socioeconomic status of the area in which the 
general practice resides where the patient was registered (quin-
tiles by rank of Indices of Multiple Deprivation), and region of 
residence (defi ned based on the location of the practice as either 
one of the 10 regions of England mapping to the government 
offi  ces of the regions, or the other countries forming the United 
Kingdom: Wales, Scotland, or Northern Ireland ). Th e age catego-
ries were selected  a priori , and children were separated into under 
5 years and 5 – 18 years, as previous literature has shown a peak in 
incidence for children under 5 years of age . Incidence rates were 
presented per 100,000 person-years with a Poisson model fi tted 
to determine incidence rate ratios (IRR). Th ese IRRs were fully 
adjusted for sex, age group, calendar year, and region of residence. 
Likelihood ratio tests were used to test for departure from linear 
trend for calendar year. 
 Point prevalence of CD or DH was calculated for the 30 of June 
2011, using all cases (both incident and prevalent) that were diag-
nosed before or on this date and who were still alive and registered 
with a participating practice. We then divided by the total CPRD 
population for acceptable registered patients at that date and cal-
culated a percentage of the population with either CD or DH, and 
the respective 95 % confi dence intervals (CIs). We then applied our 
prevalence and incidence results to the estimated general popula-
tion in the United Kingdom to predict the current numbers living 
with CD and DH (and newly diagnosed) in 2011 in the whole of 
the United Kingdom based on our fi ndings. 
 Subgroup analyses .  We examined the trends in the incidence of 
CD in a number of subgroups. First, we identifi ed all patients who 
also had a diagnosis of another autoimmune disorder such as type 
1 diabetes or thyroid disease. Second, we identifi ed patients with 
symptoms of weight loss or diarrhea, or those who had a diagnosis 
of anemia in the year before diagnosis. Finally, we identifi ed all 
patients who had an endoscopy within a year of diagnosis. For 
this latter analysis, we restricted the population to those patients 
who had linked data from Hospital Episodes Statistics available 
between 2000 and 2010. 
 Sensitivity analyses .  For the fi rst sensitivity analysis, we repeated 
all our analyses restricting our case populations to those who, 
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in addition to one diagnostic record of either CD or DH, had a 
relevant prescription for a gluten-free product and / or dapsone 
and / or a second documented record of their disease. As a second 
sensitivity analysis only for DH, we broadened the case defi nition 
to include CD patients as additional DH patients if they were 
found to have a prescription for dapsone (but without a DH 
diagnostic code). 
 Stata version 12 (Stata Statistical Soft ware, College Station, TX) 
 was used for all statistical analyses. 
 RESULTS 
 A total of 9,087 incident cases of CD and 809 incident cases 
of DH were identifi ed between 1990 and 2011, equating to 
an overall incidence rate of 13.8 per 100,000 person-years for 
CD and 1.2 per 100,000 person-years for DH. Th ere were 220 
cases with an incident diagnosis of both DH and CD during 
the study period, equating to an incidence of 0.3 per 100,000 
person-years. 
 Incidence of CD 
 Stratifi ed incidence rates of CD by sex, age group, calendar year, 
socioeconomic status, and region of residence are displayed in 
 Table 1 . Incidence of CD was nearly twice as high in female indi-
viduals as in male individuals: adjusted IRR, 1.85 (95 % CI (1.78, 
1.94)). Incidence of CD by age showed a typical bimodal distribu-
tion, with incidence rates highest in people less than 5 years of 
age and aged between 50 and 69 years ( Table 1 ). Th e incidence 
increased overall across the 22-year period studied from 5.2 to 19.1 
per 100,000 person-years (trend IRR, 1.06 (1.05 – 1.06),  P  <  0.0001 
adjusted for age, gender, region, and socioeconomic status), but 
this masked a signifi cant interaction with age (likelihood ratio 
test  P  <  0.0001;  Figure 1 ). Incidence in those under 5 years of age 
remained relatively constant across the period studied: IRR, 1.01 
(95 % CI (0.99, 1.03),  P  <  0.0001) (linear model for year adjusted 
for sex and region). Incidence in 5 – 29-year-olds increased annu-
ally by almost 10 % each year, 5 – 17-year-olds, adjusted IRR, 1.09, 
95 % CI, 1.08 – 1.11,  P  <  0.0001); and 18 – 29-year-olds, adjusted 
IRR, 1.09 (95 % CI, 1.07 – 1.10,  P  <  0.0001). Incidence in those 
aged 30 years and more increased more moderately at  ~ 4 – 7 % a 
year. Th ere was marked regional variation in incidence, with a 
signifi cantly higher incidence seen in Northern Ireland (absolute 
incidence 22.3 per 100,000 person-years;  Figure 2 ). Th e lowest 
incidence was reported in the London region (absolute incidence 
10 per 100,000 person-years). CD incidence was also higher 
among patients registered at general practices located in less soci-
oeconomically deprived areas. 
 Incidence of DH .  Stratifi ed incidence rates of DH by sex, 
age group, calendar year, and region of residence are displayed 
in  Table 2 . Incidence of DH was almost identical in male and 
female individuals : adjusted IRR, 0.99 (95 % CI (0.87, 1.14)). 
Incidence of DH by age did not show as distinct a bimodal 
distribution as did CD, although incidence in those aged under 
5 years was greater than in those aged between 5 and 29 years 
( Table 2 ). Incidence was highest in those aged 50 – 69 years, as 
in CD. Incidence decreased overall across the 22-year period 
studied from 1.82 to 0.80 per 100,000 person-years ( Figure 3 ), 
representing a   −  4 % change in incidence per year (IRR adjusted 
for sex, age group, and region and socioeconomic status, 0.96 
(95 % CI (0.94, 0.97),  P  <  0.0001); there was no signifi cant inter-
action between age and year (likelihood ratio test,  P  =  0.3562)). 
Th ere was, however, modest regional variation in incidence, with 
absolute rates being highest in the Yorkshire and the Humber 
region ( Figure 4 ). Th ere was no clear pattern of DH incidence 
by socioeconomic quintile. 
 Prevalence of CD and DH .  On 30 June 2011, there were 10,872 
people with CD who were alive and contributing data, which cor-
responded to a point prevalence of 0.24 % across the entire popu-
lation or 1 in every 420 people. Th e prevalence was substantially 
higher in female individuals than in male individuals, and it in-
creased with increasing age. Th e prevalence of DH was much low-
er at 0.03 % ( n  =  1,160) across the entire population or 1 in every 
3,300 people. On 30 June 2011, 411 people had a diagnosis of both 
DH and CD (prevalence  =  0.01 % ) ( Table 3 ). 
 Our data set covers  ~ 6 % of the English population. On the ba-
sis of our prevalence rates, this equates to  ~ 150,000 people liv-
ing with CD and  ~ 19,000 people living with DH in the United 
Kingdom in 2011. On the basis of our incidence rates, we estimate 
that  ~ 12,000 of those with CD and 500 with DH had been newly 
diagnosed in that year. 
 Subgroup analyses .  First, we examined the trends in incidence of 
CD with an autoimmune disease of either type 1 diabetes or thy-
roid disease. Th e prevalence of a diagnosis of either type 1 diabe-
tes or thyroid disease among those with CD was around 0.9 % and 
1.3 % , respectively. Th e increase in the incidence of CD with either 
of these comorbidities (trend IRR, 1.06 (1.05 – 1.07),  P  <  0.0001) 
was unchanged from that of CD overall (IRR, 1.06 (1.05 – 1.06), 
 P  <  0.0001; both estimates adjusted for age, gender, region, and 
socioeconomic status). 
 Second, the proportion of CD patients who had symptoms of 
weight loss or diarrhea recorded in the previous year doubled 
over the study period from 25 to 51 % . Th e increase in the in-
cidence of this subgroup (adjusted trend IRR, 1.10 (1.09 – 1.11), 
 P  <  0.0001) was greater than that for CD overall. Th ere was a 
similar increase in the proportion (from 18 to 53 % ) and the 
incidence of CD, with anemia recorded in the year before diag-
nosis (adjusted trend IRR, 1.13 (1.12 – 1.13),  P  <  0.0001). 
 Th ird, we identifi ed any recording of a gastroscopy within 
a year of diagnosis for the subset of cases from primary care 
practices linked to HES between 2000 and 2010 (63 % of English 
practices). Th e proportion of CD diagnoses with a recorded en-
doscopy increased from 63 to 72 % , and aft er adjusting for age, 
gender, region, and socioeconomic status the trend persisted 
(trend IRR, 1.11 (1.10 – 1.12),  P  <  0.0001). 
 Sensitivity analyses .  Th e results for incidence overall strati-
fi ed by year when we restricted our CD case population to only 
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 Table 1 .  Incidence of celiac disease 
  Cases  Person-years  Incidence rate (per 100,000 person-years) (95 % CI)  
 All  9,087  65,856,848  13.80  (13.52, 14.08)  Incidence rate ratio a (95 % CI) 
 Sex 
  Male  3,137  32,679,920  9.60  (9.27, 9.94)  1.00 (ref) 
  Female  5,950  33,176,929  17.93  (17.48, 18.40)  1.85 (1.78, 1.94) 
 Age group 
   <  5  390  2,550,088  15.29  (13.81, 16.89)  1.00 (ref) 
  5 – 17  929  10,140,413  9.16  (8.58, 9.77)  0.59 (0.52, 0.66) 
  18 – 29  809  8,922,980  9.07  (8.45, 9.71)  0.59 (0.53, 0.67) 
  30 – 49  2,768  19,716,119  14.04  (13.52, 14.57)  0.91 (0.82, 1.01) 
  50 – 69  2,916  16,041,746  18.18  (17.52, 18.85)  1.15 (1.03, 1.28) 
  70  +   1,275  8,485,502  15.03  (14.21, 15.87)  0.91 (0.82, 1.02) 
 Year 
  1990  51  988,225  5.16  (3.84, 6.79)  1.00 (ref) 
  1991  95  968,428  9.81  (7.94, 11.99)  1.84 (1.31, 2.58) 
  1992  75  1,145,736  6.55  (5.15, 8.21)  1.23 (0.86, 1.75) 
  1993  84  1,302,251  6.45  (5.15, 7.99)  1.22 (0.86, 1.72) 
  1994  93  1,402,018  6.63  (5.35, 8.13)  1.25 (0.89, 1.76) 
  1995  117  1,502,788  7.79  (6.44, 9.33)  1.46 (1.05,2.03) 
  1996  137  1,707,438  8.02  (6.74, 9.49)  1.50 (1.09, 2.07) 
  1997  155  2,037,465  7.61  (6.46, 8.90)  1.42 (1.03, 1.95) 
  1998  241  2,320,549  10.39  (9.12, 11.78)  1.93 (1.43, 2.62) 
  1999  322  2,732,415  11.78  (10.53, 13.14)  2.19 (1.63, 2.94) 
  2000  367  3,230,521  11.36  (10.23, 12.58)  2.11 (1.58, 2.83) 
  2001  422  3,522,256  11.98  (10.86, 13.18)  2.23 (1.66,2.98) 
  2002  485  3,773,659  12.85  (11.73, 14.05)  2.38 (1.79,3.18) 
  2003  578  3,927,535  14.72  (13.54, 15.97)  2.72 (2.04,3.62) 
  2004  504  4,066,850  12.39  (11.33, 13.52)  2.29 (1.72, 3.06) 
  2005  617  4,184,895  14.74  (13.60, 15.95)  2.73 (2.05, 3.63) 
  2006  636  4,228,443  15.04  (13.89, 16.26)  2.78 (2.09, 3.70) 
  2007  673  4,270,604  15.76  (14.59, 17.00)  2.92 (2.20, 3.88) 
  2008  768  4,269,975  17.99  (16.74, 19.30)  3.34 (2.51, 4.43) 
  2009  722  4,282,448  16.86  (15.65, 18.14)  3.13 (2.36, 4.16) 
  2010  808  4,218,998  19.15  (17.85, 20.52)  3.56 (2.68, 4.73) 
  2011  790  4,127,638  19.14  (17.83, 20.52)  3.55 (2.68, 4.72) 
 Region 
  North East  146  1,355,821  10.77  (9.09, 12.66)  1.00 (ref) 
  North West  1,121  8,425,342  13.31  (12.54, 14.11)  1.18 (0.99, 1.40) 
  Yorkshire and The Humber  383  2,993,984  12.79  (11.54, 14.14)  1.22 (1.01, 1.48) 
  East Midlands  396  2,758,331  14.36  (12.98, 15.84)  1.36 (1.12, 1.64) 
  West Midlands  796  5,786,860  13.76  (12.82, 14.75)  1.21 (1.01, 1.45) 
  East of England  799  6,441,340  12.40  (11.56, 13.30)  1.08 (0.90, 1.29) 
  South West  778  4,994,795  15.58  (14.50, 16.71)  1.30 (1.08, 1.55) 
Table 1 continued on the following page
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trend in the increase of CD, incidence persisted (trend IRR, 1.05 
(1.04 – 1.05),  P  <  0.0001, adjusted for age, gender, region, and so-
cioeconomic status). 
 Th e results for incidence overall stratifi ed by year when we re-
stricted our DH case population to only those individuals with 
a dapsone prescription or more than one diagnostic code, or 
broadened the DH case population to include CD with a dap-
sone prescription, are shown in  Figure 6 . Th ese results indicate 
that broadly there was a 30 – 40 % reduction in our estimated DH 
prevalence and incidence rates using the restricted population. 
However, even within this sensitivity analysis, the overall trend 
in the decrease of DH incidence persisted (trend IRR, 0.96 (0.94 –
 0.97),  P  <  0.0001, adjusted for age, gender, region, and socioeco-
nomic status). 
 DISCUSSION 
 We found that across the 22-year period of our study, there was 
a near fourfold increase in the incidence of CD in the United 
Kingdom, which contrasted starkly with a 4 % annual decrease 
in the incidence of DH. We observed some regional variation in 
both diseases across the United Kingdom, with Northern Ireland 
and Yorkshire and the Humber having the highest incidence 
rates of CD and DH, respectively, and noted that CD occurred 
more commonly among areas with least socioeconomic depriva-
tion. Our fi gures for prevalence estimate that about 3 in 10,000 
children under 5 years of age currently in the United Kingdom 
have been diagnosed with CD, with this fi gure increasing to 4 in 
1,000 adults over the age of 70 years. For DH, the prevalence esti-
mates are  ~ 10-fold lower. On the basis of our incidence fi gures, 
those individuals with a gluten-free or dapsone prescription or 
more than one diagnostic code are shown in  Figure 5 . Th ese 
results indicate that there was a 17 % reduction in our estimated 
CD prevalence and a 23 % reduction in our CD incidence rates 
by using this method. Th is reduction in the estimates did not 
vary greatly by age at diagnosis, but it did increase each year 
and varied by region in a similar way to the overall trends of 
CD for the full study. For example, the reduction in incidence 
varied by year from 14 % in 1990 to 20 % in 2010, and there was 
considerable variation by region, from 13 % in Yorkshire and 
Humber to 34 % in London. However, despite this the overall 
 Table 1 .  Continued 
  Cases  Person-years  Incidence rate (per 100,000 person-years) (95 % CI)  
 All  9,087  65,856,848  13.80  (13.52, 14.08)  Incidence rate ratio a (95 % CI) 
  South Central  1,035  7,061,717  14.66  (13.78, 15.58)  1.15 (0.97, 1.38) 
  London  715  7,183,686  9.95  (9.24, 10.71)  0.85 (0.71, 1.02) 
  South East Coast  777  5,613,311  13.84  (12.89, 14.85)  1.14 (0.95, 1.36) 
  Northern Ireland  510  2,292,558  22.25  (20.36, 24.26)  1.88 (1.56, 2.27) 
  Scotland  887  5,253,856  16.88  (15.79, 18.03)  1.36 (1.14, 1.62) 
  Wales  744  5,695,248  13.06  (12.14, 14.04)  1.11 (0.93, 1.32) 
 SES quintile      
  1 (Least deprived)  1,909  12,297,158  15.52  (14.84, 16.24)  1.00 (ref) 
  2  1,841  12,531,110  14.69  (14.03, 15.38)  0.97 (0.91, 1.04) 
  3  1,788  12,874,502  13.89  (13.25, 14.55)  0.92 (0.86, 0.98) 
  4  1,978  14,983,975  13.20  (12.63, 13.80)  0.89 (0.84, 0.95) 
  5 (Most deprived)  1,571  13,170,103  11.93  (11.35, 12.53)  0.83 (0.77, 0.89) 
 Exact / each year was included in the Poisson model as categorical, as there was a signifi cant departure from linear trend (likelihood ratio test,  P =0.0001). 
 a Adjusted for all other variables in the table. 
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 Figure 1 .  Three-year rolling average incidence of celiac disease (CD) in 
the period 1990 – 2011, by age group . 
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we estimate that in 2011  ~ 12,000 people were newly diagnosed 
with CD and 500 with DH in the United Kingdom. 
 Our study is the largest population-based study of the occur-
rence of both CD and DH, to date, providing accurate incidence 
and prevalence rates for all ages and across a longer calendar 
period than has previously been reported. Key to any measure of 
incidence is the method of defi ning the cases being counted as 
new diagnoses. In this study, we have defi ned a new case when 
an individual ’ s GP records a fi rst diagnosis of either CD or DH in 
their medical record. Such diagnoses in the United Kingdom are 
not made without a referral to secondary care and the diagnos-
tic investigations inherent within that process ( 29 – 32 ). We believe 
that this assumption is valid, as previously we have investigated the 
accuracy of the diagnosis of CD recorded electronically by GPs, 
by reviewing the medical paper records including correspond-
ence and results that emanated from secondary care ( 24 ). Th e 
agreement was improved in that validation study( 24 ) by insisting, 
within a more restrictive case defi nition, on each individual hav-
ing a prescription for a gluten-free product or a second record of 
their disease. Th is case defi nition increased the specifi city; a posi-
tive predictive value for a single code was 81 % , for a gluten-free 
prescription it was 89 % , and for two diagnostic codes it was 100 % . 
However, this had the disadvantage of reducing the sensitivity of 
our case defi nition. We therefore used a single diagnostic code to 
maximize the sensitivity in the main analysis of our current study 
and used the more specifi c defi nition in the sensitivity analysis. We 
found that 80 % of celiac patients had a prescription for a gluten-
free product or multiple codes, which was entirely consistent with 
external data in previously published surveys of local regions and 
populations. First, Hall  et al. ( 33 ) conducted a questionnaire study 
of a sample of CD patients identifi ed by Read codes in north east 
England, and reported that only 86 % received a gluten-free pre-
scription. In addition, only 3 % of those identifi ed who returned 
the questionnaire stated that they did not have CD, which provides 
additional evidence to support our use of Read codes in defi ning 
CD. Furthermore, Coeliac UK ’ s commercial team surveyed their 
own members in 2012 and found that only 75 % of members were 
using gluten-free prescriptions (Coeliac UK (2012)) Prescriptions 
Report), and in May 2013 a repeat survey in Oxford found that 
80 % of their members used gluten-free prescriptions (Coeliac 
UK (2013) Impact Oxfordshire Report). Our study ’ s fi nding for 
the whole of the United Kingdom that about 80 % of CD patients 
are having a gluten-free prescription is therefore what would be 
expected. 
 It is possible that we would have underestimated our DH inci-
dence rates if doctors have not recorded this additional diagno-
sis in people with CD as well. We assessed this potential bias by 
including CD patients with a dapsone prescription (but no diag-
nostic record of DH) in our sensitivity analysis. Th e incidence rates 
for DH when we did this, however, remained broadly similar to 
those from comparable studies, and thus we think that it is unlikely 
to have introduced a large bias. 
 When trying to assess the incidence or prevalence of any chronic 
disease such as CD or DH, it is not possible to identify the moment 
of biological onset but rather the date of acquisition of a diagnosis. 
Our defi nition of incidence relies on the fact that a GP will record 
the diagnosis of a new disease at the time the diagnosis is made, 
i.e., representing the real world of clinical practice. Measuring the 
incidence and prevalence of a disease requires an unbiased, general 
population-based sample from which the cases can arise and be 
counted. In that regard, we are fortunate that the CPRD is, broadly 
speaking, representative of the UK population as a whole. Th e only 
group of people that seems to be underrepresented in our popu-
lation are those aged 18 – 25 years, which may be because people 
in this age group are more mobile ( 34 ). Th is could have led to an 
8–10
10–12
12–14
14–16
16–18
18–20
20–22
Incidence
per 100,000 person-year
22–24
Average incidence of
celiac disease 1990–2011
in England, Northern Ireland, Scotland, and Wales
(in English regions by government office)
 Figure 2 .  Map of incidence of celiac disease (CD) by regional government 
offi ce. 
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 Table 2 .  Incidence of dermatitis herpetiformis 
  Cases  Person-years  Incidence rate (per 100,000 person-years) (95 % CI)  
 All  809  65,856,848  1.23  (1.15, 1.32)  Incidence rate ratio a (95 % CI) 
 Sex 
  Male  395  32,679,920  1.21  (1.09, 1.33)  1.00 (ref) 
  Female  414  33,176,929  1.25  (1.13, 1.37)  0.99 (0.87, 1.14) 
 Age group 
  <  5  18  2,550,088  0.71  (0.42, 1.12)  1.00 (ref) 
  5 – 17  47  10,140,413  0.46  (0.34, 0.62)  0.66 (0.39, 1.14) 
  18 – 29  61  8,922,980  0.68  (0.52, 0.88)  0.97 (0.57, 1.64) 
  30 – 49  223  19,716,119  1.13  (0.99, 1.29)  1.61 (0.99, 2.59) 
  50 – 69  311  16,041,746  1.94  (1.73, 2.17)  2.78 (1.73, 4.48) 
   >  69  149  8,485,502  1.76  (1.49, 2.06)  2.51 (1.54, 4.10) 
 Year 
  1990  18  988,225  1.82  (1.08, 2.88)  0.96 (0.94, 0.97) b 
  1991  24  968,428  2.48  (1.59, 3.69)  
  1992  26  1,145,736  2.27  (1.48, 3.33)  
  1993  21  1,302,251  1.61  (1.00, 2.47)  
  1994  20  1,402,018  1.43  (0.87, 2.20)  
  1995  21  1,502,788  1.40  (0.87, 2.14)  
  1996  29  1,707,438  1.70  (1.14, 2.44)  
  1997  30  2,037,465  1.47  (0.99, 2.10)  
  1998  35  2,320,549  1.51  (1.05, 2.10)  
  1999  47  2,732,415  1.72  (1.26, 2.29)  
  2000  49  3,230,521  1.52  (1.12, 2.01)  
  2001  48  3,522,256  1.36  (1.00, 1.81)  
  2002  52  3,773,659  1.38  (1.03, 1.81)  
  2003  52  3,927,535  1.32  (0.99, 1.74)  
  2004  26  4,066,850  0.64  (0.42, 0.94)  
  2005  50  4,184,895  1.19  (0.89, 1.58)  
  2006  56  4,228,443  1.32  (1.00, 1.72)  
  2007  44  4,270,604  1.03  (0.75, 1.38)  
  2008  43  4,269,975  1.01  (0.73, 1.36)  
  2009  45  4,282,448  1.05  (0.77, 1.41)  
  2010  33  4,218,998  0.78  (0.54, 1.10)  
  2011  33  4,127,638  0.80  (0.55, 1.12)  
 Region 
  North East  8  1,355,821  0.59  (0.25, 1.16)  1.00 (ref) 
  North West  108  8,425,342  1.28  (1.05, 1.55)  2.15 (1.05, 4.42) 
  Yorkshire and The Humber  64  2,993,984  2.14  (1.65, 2.73)  3.37 (1.61, 7.05) 
  East Midlands  36  2,758,331  1.31  (0.91, 1.81)  2.03 (0.94, 4.38) 
  West Midlands  71  5,786,860  1.23  (0.96, 1.55)  2.07 (1.00, 4.31) 
  East of England  74  6,441,340  1.15  (0.90, 1.44)  1.84 (0.88, 3.84) 
  South West  52  4,994,795  1.04  (0.78, 1.37)  1.69 (0.80, 3.58) 
Table 2 continued on the following page
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overestimate of the occurrence of disease in this age group in our 
study if those with disease are motivated to remain actively regis-
tered with a GP, regardless of their location, and are counted there-
fore in the numerator, in contrast to individuals in that age group 
who are healthy and may not register with a GP on relocation and 
therefore not appear in the denominator. 
 Prior studies on the incidence and prevalence of clinically 
diagnosed CD and DH in the general population that are com-
parable to our own are scarce  (9), and all have a smaller sample 
size. Most studies have focussed on either CD or DH separately 
rather than describing the occurrence of both diseases drawn from 
the same population, or they have focussed on either children or 
adults or have reported only incidence or prevalence. Four  popula-
tion-based studies from Sweden ( 8 ), Denmark  (5), and Scotland, 
United Kingdom ( 6,20 ) have measured the incidence of CD in 
children using information from the whole of these nations. In 
Swedish children under the age of 15 years, the reported annual 
rates increased from 19 to 44 per 100,000 over the period 1998 –
 2003 for the whole country. Th e authors speculate that this par-
ticularly high rate was a consequence of high gluten consumption. 
By contrast, in Denmark, the rates among children under the age 
of 18 ranged from 2.8 to 12.3 per 100,000 in the period 1999 – 2008. 
In Scotland, the annual age- and sex-standardized incidence rate 
reported for children under the age of 16 years between 2009 and 
2010 was 10 per 100,000  (6) . When we also restricted our popula-
tion to only Scottish practices, 2009 to 2010, under the age of 16 
years, we found a comparable rate of 12.3 (95 % CI, 8.5 – 17.3) per 
100,000 peson-years. Of the previously published studies, only the 
Danish study quantifi ed  prevalence reporting that in 2010 this was 
84 per 100,000 person-years or 0.08 % , which was similar to our 
own equivalent fi nding of 90 per 100,000 person-yeras (prevalence 
in   <  18-year olds on 1 January 2010). 
 Our trends over time in adult CD diagnosis rates and preva-
lence were similar to three regional studies: two from the United 
Kingdom ( 18,35,36 ) and one in the United States ( 27 ). First, the 
numbers of diagnoses made and rates calculated in and around the 
city of Derby, UK showed a fi ve- to sixfold increase in the absolute 
numbers of adults diagnosed between 1990 and 2006, which is not 
dissimilar to our own reported relative increase in incidence rates 
( 35,36 ) Equally, an estimated prevalence from this area at the end 
 Table 2 .  Continued 
  Cases  Person-years  Incidence rate (per 100,000 person-years) (95 % CI)  
 All  809  65,856,848  1.23  (1.15, 1.32)  Incidence rate ratio a (95 % CI) 
  South Central  89  7,061,717  1.26  (1.01, 1.55)  2.22 (1.07, 4.61) 
  London  75  7,183,686  1.04  (0.82, 1.31)  1.86 (0.89, 3.87) 
  South East Coast  62  5,613,311  1.10  (0.85, 1.42)  1.88 (0.89, 3.94) 
  Northern Ireland  27  2,292,558  1.18  (0.78, 1.71)  2.18 (0.98, 4.81) 
  Scotland  72  5,253,856  1.37  (1.07, 1.73)  2.50 (1.20, 5.20) 
  Wales  71  5,695,248  1.25  (0.97, 1.57)  2.12 (1.02, 4.41) 
 SES quintile 
  1  153  12,297,158  1.24  (1.05, 1.46)  1.00 (ref) 
  2  144  12,531,110  1.15  (0.97, 1.35)  0.93 (0.74, 1.17) 
  3  180  12,874,502  1.40  (1.20, 1.62)  1.15 (0.92, 1.44) 
  4  164  14,983,975  1.09  (0.93, 1.28)  0.86 (0.69, 1.09) 
  5  168  13,170,103  1.28  (1.09, 1.48)  1.01 (0.81, 1.27) 
 Year was included in the model as a continuous variable, as there was no signifi cant departure from a linear trend (likelihood ratio test,  P =0.1886). 
 a Adjusted for all other variables in the table. 
 b Model fi tted a linear trend. IRR=1 year increase in calendar time. 
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 Figure 3 .  Three-year rolling average incidence rates of dermatitis herpeti-
formis (DH) in the period 1990 – 2011, by age group . 
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among selected populations, therefore hindering valid compari-
sons. In the United States, for example, among military person-
nel, a low rate of 3.5 per 100,000 person-years was observed, and 
between 1999 and 2008 the rates increased 5 – 10-fold; however, 
this occupational population was relatively young and considered 
reasonably healthy by the authors ( 17 ). 
 For DH, the most comprehensive study is that from Finland by 
Salmi  et al. , ( 22 ) which measured incidence over a 30-year period 
(following an original report in 2007 ( 21 )) and elegantly summa-
rized the existing literature before its publication Th ey observed 
an overall annual incidence rate among children and adults, which 
decreased substantially over the period of the study from 5.2 to 2.7 
per 100,000 person-years in the period 1970 – 2009. Our rates were 
lower but showed a similar rate of decline. Previous prevalence 
of 1999 was around 0.14 % ( 24 ) and was similar to our estimate 
of 0.11 % for 1999. Second, a small study of CD incidence in East 
Dorset, UK, found an increase from 6.0 to 13.3 per 100,000 per-
son-years in 1993 – 2002, which was also similar to our national 
estimates ( 18 ). In contrast, the third study from the United States 
showed a plateau of diagnosis rates in the past 6 years of their study 
(2004 – 2010), potentially indicating a ceiling to CD case fi nding 
through clinical presentation. 
 Other studies have reported incidence in adults, but these are 
mostly from periods before the beginning of our study period or 
Incidence
per 100,000 person-year
2–2.25
1.75–2
1.5–1.75
1.25–1.5
1–1.25
0.75–1
0.5–0.75
Average incidence of
dermatitis herpetiformis 1990–2011
in England, Northern Ireland, Scotland, and Wales
(in English regions by government office)
 Figure 4 .  Map of incidence of dermatitis herpetiformis (DH) by regional 
government offi ce. 
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 Figure 5 .  Incidence of celiac disease (CD) overall, and when the defi nition 
is restricted to either two diagnostic codes or a gluten-free prescription. 
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 Figure 6 .  Incidence of dermatitis herpetiformis (DH) overall, the restricted 
defi nition to either two diagnostic codes or a dapsone or gluten-free 
prescription, and the broader defi nition including celiac disease (CD) 
patients with a prescription for dapsone. 
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estimates from the 1970s ( 22 ) onward in Europe and the United 
States range from 10 per 100,000 person-years or 0.01 % to 75 per 
100,000 person-years in the Finnish study or 0.075 % , a range that 
includes our own overall estimate of 0.03 % . 
 Although we believe that the close correlation of our results 
with previous data, as well as the robustness of our methodology, 
should reassure readers that our results are correct, there are two 
major fi ndings that need to be further explained. Th ese fi ndings 
are, fi rst, the marked regional and socioeconomic variations in CD 
but not DH, and second the contrasting increase in CD while DH 
decreased. Our fi ndings of considerable regional and socioeco-
nomic variation in incidence rates may indicate either that there is 
true variation in incidence or that ascertainment of disease varies. 
Th e lowest regional incidence was seen in London, and a true vari-
ation in incidence by population characteristics such as ethnicity 
and mobility may be a contributing factor to this lower observed 
incidence  (34,37). However, we believe that it is more plausible 
that these observed variations in incidence are mediated through 
disparities in health-seeking behavior and access to correct diag-
nostic pathways. Th is is partly because in the more stable, less 
ethnically diverse populations of the United Kingdom, where data 
on seroprevalence of undetected CD are available, i.e., Cambridge 
( 38 ), Bristol  (39), and Northern Ireland  (40), this is almost iden-
tical at about 1 % , yet the respective regional CD incidence rates 
in our study were 12, 15, and 22 per 100,000 person-years, cover-
ing almost the entire range of regional incidence rates we report. 
Th ese seroprevalence studies ( 38 – 40 ) also report very little varia-
tion in undetected CD prevalence in the United Kingdom by age 
and sex, suggesting that indeed health-care utilization is the most 
likely reason for the lower diagnosis rates in men and in certain 
age groups that we observed. Th is interpretation is also likely to 
be generalizable to other health-care systems in other countries, as 
similar disparities have been observed in Olmsted County, Min-
nesota ( 4,41 ) and the whole of Finland ( 42,43 ) between clinically 
diagnosed incidence and prevalence estimates and seroprevalence 
studies. 
 Table 3 .  Point prevalence of celiac disease and dermatitis herpetiformis, 30 June 2011 
  Celiac disease 
( n ) 
 Prevalence 
( % ) 
 95 % CI  Dermatitis 
herpetiformis ( n ) 
 Prevalence 
( % ) 
 95 % CI 
 Overall  10,872  0.24  (0.24, 0.25)  1,160  0.03  (0.02, 0.03) 
 Sex 
  Male  3,662  0.16  (0.16, 0.17)  560  0.03  (0.02, 0.03) 
  Female  7,210  0.32  (0.31, 0.32)  600  0.03  (0.02, 0.03) 
 Age group 
   <  5  93  0.03  (0.03, 0.04)  7  0.00  (0.00, 0.00) 
  5 – 17  903  0.13  (0.13, 0.14)  38  0.01  (0.00, 0.01) 
  18 – 29  1,026  0.15  (0.14, 0.16)  64  0.01  (0.01, 0.01) 
  30 – 49  2,952  0.23  (0.22, 0.24)  245  0.02  (0.02, 0.02) 
  50 – 69  3,948  0.37  (0.36, 0.38)  491  0.05  (0.04, 0.05) 
  70  +   1,950  0.38  (0.36, 0.40)  315  0.06  (0.05, 0.07) 
 Region 
  North East  171  0.22  (0.18, 0.25)  22  0.03  (0.02, 0.04) 
  North West  1,267  0.24  (0.22, 0.25)  121  0.02  (0.02, 0.03) 
  Yorkshire and The Humber  276  0.26  (0.23, 0.30)  47  0.04  (0.03, 0.06) 
  East Midlands  226  0.28  (0.24, 0.32)  23  0.03  (0.02, 0.04) 
  West Midlands  944  0.25  (0.23, 0.27)  91  0.02  (0.02, 0.03) 
  East of England  819  0.23  (0.22, 0.25)  86  0.02  (0.02, 0.03) 
  South West  1,072  0.28  (0.26, 0.30)  106  0.03  (0.02, 0.03) 
  South Central  1,408  0.25  (0.24, 0.26)  148  0.03  (0.02, 0.03) 
  London  905  0.16  (0.15, 0.17)  87  0.02  (0.01, 0.02) 
  South East Coast  1,019  0.23  (0.22, 0.25)  82  0.02  (0.01, 0.02) 
  Northern Ireland  592  0.39  (0.36, 0.42)  67  0.04  (0.03, 0.06) 
  Scotland  1,203  0.27  (0.26, 0.29)  166  0.04  (0.03, 0.04) 
  Wales  970  0.22  (0.21, 0.24)  114  0.03  (0.02, 0.03) 
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 Study Highlights 
 WHAT IS CURRENT KNOWLEDGE 
 3 Celiac disease (CD) incidence appears to be rising 
worldwide, and in Finland the incidence of dermatitis 
herpetiformis (DH) appears to be decreasing. 
 3 Variation by age, sex, time, and geography in the United 
Kingdom in the incidence of CD and DH is not well 
documented. 
 WHAT IS NEW HERE 
 3 CD incidence has increased in the United Kingdom over 
the past 20 years in all age groups, except those less than 
5 years of age. 
 3 DH incidence has decreased over the past 20 years in all 
age groups. 
 3 There is variation in the rates of diagnosis of CD but not DH 
throughout the United Kingdom, suggesting that opportuni-
ties for better ascertainment could be implemented.  
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 Th us, the most logical explanation for the signifi cant increase 
in incidence of CD over time is that there has been a substantial 
improvement in the diagnostic ascertainment of CD over the 
period studied. For DH, the same logic can be applied, except that 
for this disease we would have to hypothesize that diagnostic ascer-
tainment has become worse over time to explain the decline. Given 
that DH is a visible, itchy, blistering condition of extensor surfaces 
of the skin  (44), it seems highly unlikely that the reduction in inci-
dence that we, and others, have observed is related to a poorer 
pick-up rate, and thus we believe that the observed reduction is a 
true one. By contrast, the mechanisms by which CD is identifi ed 
and diagnosed have changed and improved over our study period 
with the introduction of routinely available serological tests, rapid 
and improved access to endoscopic services, and greater awareness 
among patients and doctors. Th erefore, the likelihood is that for 
CD greater ascertainment, rather than a true increase in incidence, 
explains our results. Of course, if ascertainment is increased when 
the pool of clinical disease itself is not, the observed increase in 
incidence would most likely occur through an increase in the diag-
nosis of milder or earlier cases. Th is leads to the speculation that 
the relationship between the trends over time for CD and DH were 
not independent, as proposed by Salmi  et al. ( 22 ). If we consider 
DH to be a consequence of untreated CD  per se , then by identify-
ing and treating earlier and milder CD we may be preventing the 
skin manifestations from presenting. Th is is in eff ect proposing at 
an individual level, the hypothesis previously proposed at a popu-
lation level to explain the decline in DH in Finland where gluten 
consumption has declined nationally ( 22,45 ). However, such a 
hypothesis requires far more evidence before it could be consid-
ered a causal explanation. 
 In conclusion, we have provided contemporary, population-
based, precise estimates of the incidence and prevalence of both 
CD and DH in the United Kingdom over a 22-year period. We 
have quantifi ed the likely burden of this disease on health-care sys-
tems and society in general. We have shown that the incidence of 
CD has risen markedly during the period of our study and that, 
by contrast, DH incidence has decreased. Th e highest incidence of 
CD was seen among the very young and over 50s, whereas a stead-
ily higher incidence with increasing age was seen for DH. Twice as 
many women as men get diagnosed with CD, and incidence rates 
vary regionally and by socioeconomic area. Th ese fi ndings raise 
the possibility that inequality in the diagnostic pathways across 
time, place, and person exist in the United Kingdom, given that it 
is thought that most sections of society appear to have a reasonably 
similar background risk of having CD. 
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